<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3abdfd10-c4e6-472e-b4eb-d4953f029132"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use INDOCYANINE GREEN for injection safely and effectively.  See full prescribing information for INDOCYANINE GREEN for injection.<br/>
      <br/>INDOCYANINE GREEN for injection, for intravenous <content styleCode="bold">or interstitial use</content>
      <br/>Initial U.S. Approval: 1959</title>
   <effectiveTime value="20250413"/>
   <setId root="a6f24787-c243-445a-9c55-7c7479b292d9"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="985716301" root="1.3.6.1.4.1.519.1"/>
            <name>Renew Pharmaceuticals Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="340876986" root="1.3.6.1.4.1.519.1"/>
                        <name>Umforana Labor für Umweltanalytik und Auftragsforschung GmbH &amp; Co. KG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70100-424" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b5ef740e-7d57-47c6-b3fc-91bf1e4f9a4a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250413"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70100-424" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Indocyanine Green</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Indocyanine Green and Water</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="6"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70100-424-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20080101"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Indocyanine Green</name>
                              <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Indocyanine Green</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="25"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="IX6J1063HV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INDOCYANINE GREEN</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="C4V974V932" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>INDOCYANINE GREEN ACID FORM</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA040811" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38219" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTERSTITIAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0409-4887" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>WATER</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-4887-17" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43214" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, PLASTIC"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA018801" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19821027"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38219" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTERSTITIAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040811" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080101"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_926d3d72-fb2d-4177-9df4-35403b169c80">
               <id root="3fdf30c0-4cab-4149-8a5f-272dd6b8c2c8"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Indications and Usage, For determining Cardiac Output, Hepatic Function, and Liver Blood Flow (1.1) Removed                                                                                          12/2024</paragraph>
                        <paragraph>Indications and Usage (<linkHtml href="#ID_3392ad6e-d1d2-4c46-bd7d-18945fdd58a2">1.1</linkHtml>, <linkHtml href="#ID_79243518-7c70-42be-a48e-d827b08352e7">1.2</linkHtml>, <linkHtml href="#ID_345d0a1a-e4bb-4986-ae9e-3f7f7cc43ab9">1.3</linkHtml>)                                                                 12/2024</paragraph>
                        <paragraph>Dosage and Administration, Indicator-Dilution Studies and Hepatic Function Studies (2.1, 2.2) Removed                                                                                                            12/2024</paragraph>
                        <paragraph>Dosage and Administration (<linkHtml href="#ID_2e42a9ed-e322-4057-9c67-29dcb5568a8a">2.1</linkHtml>, <linkHtml href="#ID_88f2536e-fdff-40e5-b841-ff5921fa1aee">2.2</linkHtml>, <linkHtml href="#ID_7071103f-283d-4312-843c-237d61ba59cf">2.3</linkHtml>, <linkHtml href="#ID_2cf5ffcf-1dc7-4618-81b1-1fe5bff88bd5">2.5</linkHtml>)                                                  12/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_6591b6c7-5d07-4964-a802-b086bbb3ca14">
               <id root="42bf0778-8fee-43e5-9283-8c01751f540a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Indocyanine Green for injection is indicated:</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indocyanine Green for injection is an optical imaging agent indicated for:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older (<linkHtml href="#ID_3392ad6e-d1d2-4c46-bd7d-18945fdd58a2">1.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older (<linkHtml href="#ID_79243518-7c70-42be-a48e-d827b08352e7">1.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer (<linkHtml href="#ID_345d0a1a-e4bb-4986-ae9e-3f7f7cc43ab9">1.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Ophthalmic angiography in adults and pediatric patients (<linkHtml href="#ID_36ebfaa0-1827-4a08-8b40-96b0c9ab61e7">1.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_3392ad6e-d1d2-4c46-bd7d-18945fdd58a2">
                     <id root="57903d39-7222-4533-9eef-6fdb62d285f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green is indicated for fluorescence imaging of vessels (micro- and macro- vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients aged 1 month and older.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_79243518-7c70-42be-a48e-d827b08352e7">
                     <id root="8f175883-07a9-45d7-9176-0eac058845de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.2 Visualization of Extrahepatic Biliary Ducts</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_345d0a1a-e4bb-4986-ae9e-3f7f7cc43ab9">
                     <id root="43884837-0926-4f0f-b49f-2398f05bb046"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.3 Lymphatic Mapping of Cervical and Uterine Cancer</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_36ebfaa0-1827-4a08-8b40-96b0c9ab61e7">
                     <id root="c1f55326-6ab5-4975-9ff2-27818fc42f2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Ophthalmic Angiography </title>
                     <text>
                        <paragraph>Indocyanine Green is indicated for use in ophthalmic angiography in adults and pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_679e6487-bc4f-423a-90df-144f9112641f">
               <id root="1d50e0c2-5932-4317-9d0c-f119f5b2bfb5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Visualization of vessels, blood flow and tissue perfusion (2.5 mg/mL solution)<list listType="unordered">
                                 <item>
                                    <caption>o</caption>1.25 mg to 5 mg by intravenous injection is recommended for a surgical procedure in adults and pediatric patients aged 1 month and older.</item>
                                 <item>
                                    <caption>o</caption>3.75 mg to 10 mg by intravenous injection is recommended for visualization of perfusion in extremities through the skin for plastic, micro- and reconstructive surgeries in adults.</item>
                                 <item>
                                    <caption>o</caption>Additional doses may be administered. Do not exceed a total dose of 2 mg/kg. (<linkHtml href="#ID_2e42a9ed-e322-4057-9c67-29dcb5568a8a">2.1</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older (2.5 mg/mL solution)<list listType="unordered">
                                 <item>
                                    <caption>o</caption>2.5 mg by intravenous injection at least 45 minutes prior to surgery.</item>
                                 <item>
                                    <caption>o</caption>Additional doses may be administered. Do not exceed a total dose of 2 mg/kg. (<linkHtml href="#ID_88f2536e-fdff-40e5-b841-ff5921fa1aee">2.2</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Lymphatic mapping of cervical and uterine cancer in adults (1.25 mg/mL solution)<list listType="unordered">
                                 <item>
                                    <caption>o</caption>5 mg interstitially as four 1 mL injections.</item>
                                 <item>
                                    <caption>o</caption>See Full Prescribing Information for injection techniques. (<linkHtml href="#ID_7071103f-283d-4312-843c-237d61ba59cf">2.3</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Ophthalmic Angiography <list listType="unordered">
                                 <item>
                                    <caption>o</caption>Doses up to 40 mg in 2 ml of Sterile Water for Injection by intravenous injection. (<linkHtml href="#ID_a1f926a6-117a-4c9d-8e00-a853d70b41e5">2.4</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>See Full Prescribing Information for reconstitution instructions. (<linkHtml href="#ID_2cf5ffcf-1dc7-4618-81b1-1fe5bff88bd5">2.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2e42a9ed-e322-4057-9c67-29dcb5568a8a">
                     <id root="ad32097c-ec7e-4634-9a8b-4b1aca5d6508"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.1 Indicator-Dilution Studies</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Dosing</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Adults:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dose of Indocyanine Green for a single image sequence for visualization of vessels, blood flow and tissue perfusion in adults is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">For visualization of perfusion in extremities through the skin in adults, the recommended dose is 3.75 mg to 10 mg administered intravenously as 1.5 mL to 4 mL of a 2.5 mg/mL solution.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Immediately flush with a 10 mL bolus of 0.9% Sodium Chloride Injection.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Pediatric patients aged 1 month and older:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dose of Indocyanine Green for a single image sequence for visualization of vessels, blood flow and tissue perfusion in pediatric patients aged 1 month and older is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution. Lower doses may be administered in younger patients and in those with lower body weight. Adjust the amount and type of flush to avoid volume and/or sodium overload.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In both adults and pediatric patients aged 1 month and older, additional doses may be administered to obtain imaging sequences during the procedure. Do not exceed the maximum total dose of 2 mg/kg.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Administration</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Prior to the imaging procedure, draw up the desired dose of Indocyanine Green solution into appropriate syringes and prepare a 10 mL syringe of 0.9% Sodium Chloride Injection.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Administer via a central or peripheral venous line using a three-way stopcock attached to an injection port on the infusion line. Inject the prepared Indocyanine Green into the line as a tight bolus. Immediately switch the access on the stopcock and inject the prepared flush.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Imaging Instructions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_88f2536e-fdff-40e5-b841-ff5921fa1aee">
                     <id root="b6c9b5fa-5945-4e4a-b0c6-e6dc818696c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.2 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Dosing and Administration</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dose of Indocyanine Green for visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older is 2.5 mg administered intravenously as 1 mL of a 2.5 mg/mL solution at least 45 minutes prior to surgery.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Additional doses may be administered to obtain imaging sequences during the procedure.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Do not exceed a total dose of 2 mg/kg.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Imaging Instructions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Fluorescence is visible in the biliary tree within 45 minutes after injection.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7071103f-283d-4312-843c-237d61ba59cf">
                     <id root="de5451dc-c29a-4c16-ac6a-87c2dac02a2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.3 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Dosing and Administration</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dose of Indocyanine Green for lymphatic mapping of cervical and uterine cancer in adults is 5 mg administered interstitially as four 1 mL injections of a 1.25 mg/mL solution into the cervix, at the 3 o’ clock and the 9 o’clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Imaging Instructions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a1f926a6-117a-4c9d-8e00-a853d70b41e5">
                     <id root="229a9543-d798-4fb9-92a9-b9ef04a40fa5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dose and Administration for Ophthalmic Angiography </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosing and Administration</content>
                        </paragraph>
                        <paragraph>Doses up to 40 mg Indocyanine Green in 2 mL of Sterile Water for Injection depending on the imaging equipment and technique used should be administered intravenously and immediately followed by a 5 mL bolus of 0.9% Sodium Chloride Injection. The antecubital vein can be used for Indocyanine Green administration.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2cf5ffcf-1dc7-4618-81b1-1fe5bff88bd5">
                     <id root="ebbafb0d-8bad-4f74-a0ee-f48c7b02ef43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Reconstitution Instructions </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">General</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Prepare Indocyanine Green for injection using aseptic techniques prior to procedure.</item>
                           <item>
                              <caption>•</caption>Inspect the reconstituted solution for particulate matter. The reconstituted solution should be a clear, green solution.</item>
                           <item>
                              <caption>•</caption>Use the prepared solution within 6 hours.</item>
                           <item>
                              <caption>•</caption>Discard any unused product.</item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Visualization of Vessels, Blood Flow, Tissue Perfusion and Extrahepatic Biliary Ducts </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Dissolve 25 mg of Indocyanine Green with 10 mL Sterile Water for Injection to form a concentration of 2.5 mg/mL indocyanine green.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Lymphatic Mapping of Cervical and Uterine Cancer</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Dissolve 25 mg of Indocyanine Green with 20 mL Sterile Water for Injection to form a concentration of 1.25 mg/mL indocyanine green.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Ophthalmic Angiography</content>
                        </paragraph>
                        <paragraph>Dissolve doses up to 40 mg of Indocyanine Green with 2 mL Sterile Water for Injection.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_292e2010-8caa-438a-a395-297fb2aa505b">
               <id root="352c4393-1400-4eb6-8ec3-7e4dc9f05881"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>For injection: 25 mg of indocyanine green as a sterile, lyophilized, green powder for reconstitution provided in a 25 mL single-patient-use vial.</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 25 mg of indocyanine green as a lyophilized, green powder for reconstitution in a single-patient-use vial  (<linkHtml href="#ID_292e2010-8caa-438a-a395-297fb2aa505b">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_a4f6b267-5d2f-4d68-94ca-89e2de96ecaf">
               <id root="cbe26da5-1bbb-4650-bbab-a7a195371b53"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Indocyanine Green is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_c9dc09e2-e53f-4af5-9d7c-40b0ffb70720">5.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to indocyanine green (<linkHtml href="#ID_a4f6b267-5d2f-4d68-94ca-89e2de96ecaf">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_5fe46e3d-42a5-48d7-b317-08aa26998869">
               <id root="af651b02-ac73-45b8-beca-610588bc3352"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity reactions: Hypersensitivity reactions including  anaphylaxis and urticaria have occurred. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor patients. (<linkHtml href="#ID_c9dc09e2-e53f-4af5-9d7c-40b0ffb70720">5.1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c9dc09e2-e53f-4af5-9d7c-40b0ffb70720">
                     <id root="92ade338-c966-4045-a141-02073b160740"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Hypersensitivity reactions including anaphylaxis, urticaria and deaths due to anaphylaxis have been reported following intravenous administration of Indocyanine Green <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_f0712aa5-7f8c-4175-8fcd-c26a3c2efcb4">6</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Indocyanine Green is contraindicated in patients with a history of hypersensitivity to indocyanine green <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_a4f6b267-5d2f-4d68-94ca-89e2de96ecaf">4</linkHtml>)]</content>. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a6b91c1b-e7e8-46cd-9da0-c8fe0065fb64">
                     <id root="f7dc7b27-e355-4bfc-8dcd-19302bc18e51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Interference with Thyroid Radioactive Iodine Uptake Studies </title>
                     <text>
                        <paragraph>Because Indocyanine Green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_1b1d2f5e-9fd7-4104-a7ec-cf722ccecf64">7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f0712aa5-7f8c-4175-8fcd-c26a3c2efcb4">
               <id root="e46643ae-ebff-4d80-9ac8-8ab1a0efb0a0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_c9dc09e2-e53f-4af5-9d7c-40b0ffb70720">5.1</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>The following adverse reactions have been identified during post-approval use of Indocyanine Green. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune System Disorders</content>: Anaphylaxis, urticaria</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions reported are anaphylaxis and urticaria.  (<linkHtml href="#ID_f0712aa5-7f8c-4175-8fcd-c26a3c2efcb4">6</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Diagnostic Green LLC at 1-844-424-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1b1d2f5e-9fd7-4104-a7ec-cf722ccecf64">
               <id root="913ced2c-d146-4f6b-8789-2396185b7bc2"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Interference with Thyroid Radioactive Iodine Uptake Studies</content>
                  </paragraph>
                  <paragraph>Because Indocyanine Green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of Indocyanine Green.</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Interference with Thyroid Radioactive Iodine Uptake Studies: Do not perform radioactive iodine uptake studies for at least one week following the use of Indocyanine Green. (<linkHtml href="#ID_1b1d2f5e-9fd7-4104-a7ec-cf722ccecf64">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4c89ab40-48d1-4489-8397-7190292fbe12">
               <id root="1a713945-e9cd-4138-bccc-93e4db4917ee"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250413"/>
               <component>
                  <section ID="ID_ca933a0b-4fd4-4d35-a901-e92656199e58">
                     <id root="0fb58804-4559-4a15-8dab-2df6d201e289"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250413"/>
                     <component>
                        <section ID="ID_bfea9b20-e1c4-4b26-a251-400e21c3e96a">
                           <id root="8e32f385-4dff-41e5-9133-b3cf06f39727"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>There are no adequate and well-controlled studies of Indocyanine Green in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green.</paragraph>
                              <paragraph>All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250413"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_72a6303a-7acb-4338-a895-f278a2d816f3">
                     <id root="8d79c8ce-3f33-49d1-8bdb-c3efc2be5837"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20250413"/>
                     <component>
                        <section ID="ID_3bd4f8ea-dea5-47d3-98ac-7900e15337b5">
                           <id root="f847b62c-e0b5-4511-8ddd-3ce4fcc98254"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>Risk Summary </title>
                           <text>
                              <paragraph>Seventeen cases of indocyanine green use in lactating women have been reported in the scientific literature with no adverse events observed in the breastfed infant. However, there are no data on the presence of indocyanine green in human milk or the effects on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Indocyanine Green and any potential adverse effects on the breastfed infant from Indocyanine Green or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250413"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_69835dc0-c14d-4f0a-b0b3-06dfe748d69d">
                     <id root="6cc5bd8f-dd04-49a8-9775-c29fec135bd4"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Use of Indocyanine Green for visualization of vessels, blood flow and tissue perfusion has been established in pediatric patients aged 1 month and older. Pediatric use is supported by published data in 49 pediatric patients who received indocyanine green for assessment of blood flow and tissue perfusion in cardiovascular, vascular, and plastic, micro- and reconstructive surgical procedures, and by clinical trials in adults<content styleCode="italics">. </content>No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_2e42a9ed-e322-4057-9c67-29dcb5568a8a">2.1</linkHtml>)]. </content>The use of Indocyanine Green for visualization of vessels, blood flow and tissue perfusion has not been established in pediatric patients aged less than 1 month. </paragraph>
                        <paragraph>Use of Indocyanine Green for visualization of extrahepatic biliary ducts has been established in pediatric patients aged 12 years and older. Pediatric use is supported by clinical trials in adults in addition to clinical use in pediatric patients. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_88f2536e-fdff-40e5-b841-ff5921fa1aee">2.2</linkHtml>)]</content>. The use of Indocyanine Green for visualization of extrahepatic biliary ducts has not been established in pediatric patients aged less than 12 years.</paragraph>
                        <paragraph>Use of Indocyanine Green for visualization of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients.</paragraph>
                        <paragraph>Use of Indocyanine Green for ophthalmic angiography has been established in pediatric patients. Pediatric use is supported by evidence from the published literature.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_521eb686-8ec9-415a-9775-350199b80500">
                     <id root="30142b93-0dea-4aa1-9dd8-bd004e932f67"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the total number of patients in clinical studies of indocyanine green for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of indocyanine green for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Clinical studies of indocyanine green for visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. </paragraph>
                        <paragraph>No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7fa5d433-5ac5-4e9e-805e-6c5b6d907301">
               <id root="294f859a-d03f-43b2-9098-f34f97f02617"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Indocyanine Green for injection is an optical imaging agent for intravenous or interstitial use. </paragraph>
                  <paragraph>Each vial contains 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder.  Indocyanine Green has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP.</paragraph>
                  <paragraph>The chemical name for Indocyanine Green is 1 <content styleCode="italics">H</content>Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2<content styleCode="italics">H</content>-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt.</paragraph>
                  <paragraph>Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula:</paragraph>
                  <renderMultiMedia ID="id-517550251" referencedObject="ID_56068cc0-2b90-48d7-a091-232586eb9453"/>
                  <paragraph>Indocyanine green has a peak spectral absorption at 805 nm in blood.</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <component>
                  <observationMedia ID="ID_56068cc0-2b90-48d7-a091-232586eb9453">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9fdaa55f-55f6-4c57-9229-3cc62a62e1b6">
               <id root="eb8df5e9-cc40-447a-9b98-050ab283131d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250413"/>
               <component>
                  <section ID="ID_34d3c07f-b9a0-4429-953c-628763ae3788">
                     <id root="846c0aa7-0eae-4e95-b9f9-426afd67b7ae"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macro-vasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_42320122-c4b3-42e5-95d3-87af438bc5da">
                     <id root="1c04da50-0d7b-437b-a182-64667b9a8456"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>There are no pharmacodynamic data.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2b71bd3b-6401-4d3d-9996-72795d8d3463">
                     <id root="301b059a-3c03-4f77-9301-38613eba18b7"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin.</paragraph>
                        <paragraph>Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes.</paragraph>
                        <paragraph>Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, Indocyanine Green is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3188d46c-0c7c-4553-81c1-20267fbdafc7">
               <id root="b92071a8-7507-4519-871d-63e723e86538"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250413"/>
               <component>
                  <section ID="ID_7dbd5e96-6c4a-464a-96d4-c67a0557a3d1">
                     <id root="5ad5ee7a-123c-43ff-9247-5e4188beb20c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>No studies have been performed to evaluate the potential for carcinogenicity, mutagenicity, or impairment of fertility by indocyanine green.</paragraph>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_27dc3d56-cfb4-4a0e-acd5-5531622f7b8d">
               <id root="227b42fa-7036-444a-9616-5afb0533bd31"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20250413"/>
               <component>
                  <section ID="ID_210f81e0-83e4-4bee-8bb2-711b2f7e3c4f">
                     <id root="bb9a68aa-b430-4403-8f9a-7fac21c3fc8d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Lymphatic Mapping of Cervical and Uterine Cancer </title>
                     <text>
                        <paragraph>The effectiveness of Indocyanine Green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer has been established based on a study of another formulation of indocyanine green for injection. Below is a description of the FILM Study (NCT 02209532). </paragraph>
                        <paragraph>The study was a randomized, prospective, multi-center, open-label study in patients with early stage uterine or cervical cancer and no known regional nodal or metastatic disease by standard clinical evaluation. Indocyanine green and a blue dye comparator were injected into the cervix of patients at the beginning of the operative procedure.</paragraph>
                        <paragraph>A total of 176 patients were randomized to receive either indocyanine green followed by blue dye or blue dye followed by indocyanine green. A total of four 1 mL injections of a 1.25 mg/ml solution of indocyanine green for a total dose of 5 mg were administered interstitially into the cervix at the 3 o'clock and 9 o'clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.</paragraph>
                        <paragraph>Lymphatic mapping was performed intraoperatively using a fluorescence imaging device and standard light, followed by excision of tissues identified by indocyanine green, blue dye, or the surgeon's visual and palpation examination. The resected tissues were evaluated by histopathology to confirm presence of lymph nodes. The efficacy of indocyanine green in the detection of lymphatic vessels and lymph nodes during lymphatic mapping procedures was determined by the number of histology-confirmed lymph nodes detected by indocyanine green and/or the blue dye comparator.</paragraph>
                        <paragraph>The mean age of the 176 patients was 63 years (range: 31 to 88 years); distribution by race and ethnicity was 79% White, 4% Black or African American, 3% Asian, 13% Hispanic/Latino and 1% other.</paragraph>
                        <paragraph>
                           <linkHtml href="#_Ref194770255" title="Table 1">Table 1</linkHtml> shows the distribution of resected, confirmed lymph nodes detected by indocyanine green or blue dye in the modified intent-to-treat population (mlTT). Among the confirmed lymph nodes identified, 93% were identified using indocyanine green, and 43% were identified using blue dye, a difference of 50% [95% confidence interval 39% to 60%].</paragraph>
                        <table ID="_Ref194770255" cellpadding="3.6pt" width="75%">
                           <caption>Table 1: Distribution of Resected, Confirmed Lymph Nodes Detected by Indocyanine Green or Blue Dye (BD)</caption>
                           <col width="13%"/>
                           <col width="10%"/>
                           <col width="13%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Analysis Population</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Nodes (n)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">All Lymph Nodes Detected with Indocyanine Green</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">All Lymph Nodes Detected with BD</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Lymph Nodes Detected with Indocyanine Green Only</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Lymph Nodes Detected with BD Only</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Lymph Nodes Detected with Neither</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Toprule " valign="middle">
                                    <paragraph>mlTT</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>513</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>(476/513)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>(220/513)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>(262/513)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>(6/513)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Toprule " valign="middle">
                                    <paragraph>(31/513)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule " valign="middle">
                                    <paragraph>93%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="middle">
                                    <paragraph>43%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="middle">
                                    <paragraph>51%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="middle">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td styleCode="Lrule " valign="middle">
                                    <paragraph>6%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#_Ref194770276" title="Table 2">Table 2</linkHtml> shows the number of patients with at least one resected, confirmed lymph node and the number of patients with at least one bilateral lymph node pair detected by indocyanine green or blue dye. With indocyanine green, approximately 97% of patients had at least one resected, confirmed lymph node detected and 73% had at least one bilateral lymph node pair detected, compared with 68% and 28%, respectively, with blue dye (p-values for each analysis &lt;0.0001).</paragraph>
                        <table ID="_Ref194770276" cellpadding="3.6pt" width="75%">
                           <caption>Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node/ Bilateral Pair Detected by Indocyanine Green or Blue Dye (BD)</caption>
                           <col width="14%"/>
                           <col width="9%"/>
                           <col width="14%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7" valign="top">*: patients with at least one resected confirmed lymph node detected unilaterally<br/>**: patients with at least one resected confirmed lymph node detected bilaterally</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Analysis Population</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients (n)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients with All Lymph Nodes Detected with Indocyanine Green</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients with All Lymph Nodes Detected with BD</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients with Lymph Nodes Detected with Indocyanine Green only</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients with Lymph Nodes Detected with BD only</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients with Lymph Nodes Detected with Neither</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Toprule " valign="top">
                                    <paragraph>mlTT Unilateral*</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>172</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>(167/172)</paragraph>
                                    <paragraph>97%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>(118/172)</paragraph>
                                    <paragraph>68%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>(51/172)</paragraph>
                                    <paragraph>30%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>(2/172)</paragraph>
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td styleCode="Lrule Toprule " valign="top">
                                    <paragraph>(3/172)</paragraph>
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule " valign="top">
                                    <paragraph>mlTT Bilateral**</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>(126/172)</paragraph>
                                    <paragraph>73%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>(49/172)</paragraph>
                                    <paragraph>28%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>(79/172)</paragraph>
                                    <paragraph>46%</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>(2/172)</paragraph>
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td styleCode="Lrule " valign="top">
                                    <paragraph>(44/172)</paragraph>
                                    <paragraph>26%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a318d82b-1e45-42c8-a6e4-df7a2db09312">
               <id root="2f26ea2e-99a4-42ec-b431-ed3e12b0cf28"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>Indocyanine Green for injection is supplied as a kit (NDC 70100-424-02) containing the following:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Six 25 mL single-patient-use vials of Indocyanine Green (25 mg each) as a sterile, lyophilized green powder for reconstitution NDC 70100-424-01 </item>
                     <item>
                        <caption>•</caption>Six single-dose vials of Sterile Water for Injection (10 mL each) NDC 63323-185-10 or NDC 0409-4887-17 or NDC 0641-6147-01.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F).</paragraph>
               </text>
               <effectiveTime value="20250413"/>
            </section>
         </component>
         <component>
            <section ID="ID_99c498f9-340b-46c1-8e3e-078258b2f5ef">
               <id root="89e574c5-4546-4b8d-87eb-974292f529d2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to seek medical attention for reactions following injection of Indocyanine Green such as difficulty breathing, swollen tongue or throat, skin reactions including hives, itching and flushed or pale skin, low blood pressure, a weak and rapid pulse and other symptoms or signs of an anaphylactic reaction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_c9dc09e2-e53f-4af5-9d7c-40b0ffb70720">5.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250413"/>
            </section>
         </component>
         <component>
            <section ID="ID_156ea30e-b897-4466-b184-0b1e561e26d7">
               <id root="f7e30892-12f8-491c-94ff-2f0ae6090bd9"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>  </title>
               <text>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Patheon Italia S.p.A.<br/>20900 Monza (MB), ITALY</paragraph>
                  <paragraph>or</paragraph>
                  <paragraph>LYOCONTRACT GmbH<br/>38871 Ilsenburg, GERMANY</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Diagnostic Green LLC<br/>Farmington Hills, Ml 48331 </paragraph>
                  <paragraph>Sterile Water for injection, USP is manufactured by:</paragraph>
                  <paragraph>Fresenius Kabi USA, LLC<br/>Grand Island, NY 14072 </paragraph>
                  <paragraph>or</paragraph>
                  <paragraph>Hospira, Inc.<br/>Rocky Mount, NC 27804 </paragraph>
                  <paragraph>or</paragraph>
                  <paragraph>Hikma Pharmaceuticals USA Inc.<br/>Cherry Hill, NJ 08003</paragraph>
                  <paragraph>50426</paragraph>
               </text>
               <effectiveTime value="20250413"/>
            </section>
         </component>
         <component>
            <section ID="ID_d844cd6d-0a82-4fc5-99b9-e5604f670086">
               <id root="682d8f25-6ced-4e9f-b936-477c7f2f387f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Vial </title>
               <text>
                  <renderMultiMedia ID="id1294632760" referencedObject="FABBE1EA-7B49-4D07-889B-BE59C3ED2A27">
                     <caption>Vial Label</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 70100-424-01</paragraph>
                  <paragraph>Rx only     Sterile</paragraph>
                  <paragraph>
                     <content styleCode="bold">Indocyanine Green </content>
                     <br/>
                     <content styleCode="bold">for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">25 mg/Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Patient-Use<br/>For Intravenous or Interstitial Use</content>
                     <br/>After reconstitution, use within 6 hours.</paragraph>
                  <paragraph>Distributed by: Diagnostic Green LLC</paragraph>
                  <paragraph>50428<br/>01/2025</paragraph>
                  <paragraph>Lot No.<br/>Exp.:</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <component>
                  <observationMedia ID="FABBE1EA-7B49-4D07-889B-BE59C3ED2A27">
                     <text>Principal Display Panel - Vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e3194421-1e6b-4bfd-b4d9-c09872d7f9c4">
               <id root="5fc6a021-3a03-44a1-906d-d2c00416b072"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - STERILE WATER VIAL </title>
               <text>
                  <renderMultiMedia ID="id432402752" referencedObject="EADB960E-A655-40D0-AB5C-BFF9CAD4F982">
                     <caption>Sterile Water Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">10 mL</content>   Single-dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile Water</content>
                     <br/>for Injection, USP</paragraph>
                  <paragraph>FOR DRUG DILUENT USE</paragraph>
                  <paragraph>Rx only               NDC 0409-4887-17</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains no antimicrobial or other added<br/>substance.</content> Sterile, nonpyrogenic. Do not give<br/>intravenously unless rendered nearly isotonic.</paragraph>
                  <paragraph>Hospira, Inc.              RL-4428<br/>Lake Forest, IL 60045 USA</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <component>
                  <observationMedia ID="EADB960E-A655-40D0-AB5C-BFF9CAD4F982">
                     <text>Principal Display Panel - Sterile Water Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9ab3c008-6474-42f8-8e14-9dcc1670cf5f">
               <id root="58a65f9d-f6c2-416e-887a-358326ece05a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Carton </title>
               <text>
                  <renderMultiMedia ID="id218794204" referencedObject="ID_0fafedf5-8842-4331-9631-952b441dd4f4">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 70100-424-02               Rx Only - Sterile</paragraph>
                  <paragraph>
                     <content styleCode="bold">Indocyanine Green</content>
                     <br/>
                     <content styleCode="bold">for Injection, USP<br/>25 mg/Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Patient-Use          For Intravenous or Interstitial Use</content>
                  </paragraph>
                  <paragraph>Distributed by: Diagnostic Green LLC</paragraph>
                  <paragraph>
                     <content styleCode="underline">Back Panel</content>
                  </paragraph>
                  <paragraph>NDC 70100-424-02               Rx Only - Sterile</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage and Reconstitution<br/>Instructions: See Prescribing Information<br/>
                     </content>Use within 6 hours after reconstitution.</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content> Store at 20° to 25° C (68° to 77°F)</paragraph>
                  <paragraph>
                     <content styleCode="bold">KIT CONTAINS:</content>
                     <br/> • Six vials of Indocyanine Green (25 mg each)<br/> • Six Sterile Water for Injection (10 mL each)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Indocyanine Green</content>
                     <br/>
                     <content styleCode="bold">for Injection, USP<br/>25 mg/Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Single-Patient-Use          For Intravenous or Interstitial Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Left Panel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Indocyanine Green for</content>
                     <br/>
                     <content styleCode="bold">Injection, USP</content>
                  </paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Diagnostic Green LLC</content>
                     <br/>Farmington Hills MI <br/>48331 USA</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Patheon Italia S.p.A.<br/>
                     </content>20052 Monza (Milano) <br/>ITALY<br/>or<br/>
                     <content styleCode="bold">Lyocontract GmbH<br/>
                     </content>38871 Ilsenburg<br/>GERMANY</paragraph>
                  <paragraph>Sterile Water <br/>Manufactured by:<br/>Hospira, Inc.<br/>Rocky Mount, NC 27804<br/>or<br/>Fresenius Kabi USA, LLC<br/>Grand Island, NY 14072<br/>or<br/>Hikma Pharmaceuticals<br/>Berkeley Heights, NJ 07922</paragraph>
                  <paragraph>01/2025</paragraph>
               </text>
               <effectiveTime value="20250413"/>
               <component>
                  <observationMedia ID="ID_0fafedf5-8842-4331-9631-952b441dd4f4">
                     <text>Principal Display Panel - Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>